Skip to main content

Table 3 Day 85 SGRQ responders by patient subgroup

From: Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Subgroups

Revefenacin 175 μg

(n = 395)

Placebo

(n = 417)

ITT

 Evaluable n

288

276

 Odds ratio (95% CI)

1.53 (1.10, 2.13), p = 0.0116

 

FEV130%–< 50% pred

 Evaluable n

96

78

 Odds ratio (95% CI)

1.99 (1.04, 3.81), p = 0.0368

 

FEV1 < 30% pred

 Evaluable n

16

7

 Odds ratio (95% CI)

2 × 1010 (3.05 × 107,126 × 109), p < 0.001

 

2011 GOLD category D

 Evaluable n

103

81

 Odds ratio (95% CI)

2.52 (1.34, 4.76), p = 0.0042

 

ICS use

 Evaluable n

134

105

 Odds ratio (95% CI)

1.23 (0.74, 2.03), p = 0.4291

 

LABA or ICS/LABA use

 Evaluable n

118

85

 Odds ratio (95% CI)

1.34 (0.77, 2.35), p = 0.2995

 

> 65 years

 Evaluable n

133

119

 Odds ratio (95% CI)

1.11 (0.67, 1.84), p = 0.6897

 

> 75 years

 Evaluable n

28

25

 Odds ratio (95% CI)

0.58 (0.19, 1.81), p = 0.3506

 

Reversible to ipratropium and albuterol

 Evaluable n

66

51

 Odds ratio (95% CI)

1.12 (0.55, 2.30), p = 0.7486

 

History of CV disease

 Evaluable n

19

25

 Odds ratio (95% CI)

2.30 (0.68, 7.83), p = 0.1822

 

History of diabetes

 Evaluable n

60

53

 Odds ratio (95% CI)

1.31 (0.63, 2.75), p = 0.4704

 

History of cognitive/mental impairments

 Evaluable n

43

40

 Odds ratio (95% CI)

1.18 (0.49, 2.88), p = 0.7126

 
  1. CI confidence intervals; CV cardiovascular; FEV1 forced expiratory volume in 1 s; GOLD Global Initiative for Chronic Obstructive Lung Disease, LABA long-acting ß agonist; ICS inhaled corticosteroids; ITT intention-to-treat; pred predicted